Results 61 to 70 of about 10,302,641 (371)

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

Journal of Hematology & Oncology, 2020
VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized.
Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, Xueli Bai, Tingbo Liang   +7 more
doaj   +1 more source

Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events

Thoracic Cancer, 2021
Background The pancreatic immune‐related adverse event (irAE) is a rare but increasingly occurrence disease with limited knowledge, which was associated with the use of immune checkpoint inhibitors (ICIs).
Bei Tan, Min‐jiang Chen, Qi Guo, Hao Tang, Yue Li, Xin‐miao Jia, Yan Xu, Liang Zhu, Meng‐zhao Wang, Jia‐ming Qian   +9 more
doaj   +1 more source

Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea?

Cardiovascular Diabetology, 2014
BackgroundObstructive sleep apnea is a common disorder acting as a risk factor for the development and progression of cardiometabolic derangements including non-alcoholic fatty liver disease.
A. Mirrakhimov
semanticscholar   +1 more source

Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience. [PDF]

, 2015
The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic ...
Basso, Smm, Bidoli, E, Foltran, L, Lo Re, G, Lumachi, Franco, Santeufemia, Da   +5 more
core   +2 more sources

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Molecular Cancer, 2014
BackgroundWe investigated whether combinations of serum cytokines, used with logistic disease predictor models, could facilitate the detection of pancreatic ductal adenocarcinoma (PDAC).MethodsThe serum levels of 27 cytokines were measured in 241 ...
V. Shaw, B. Lane, C. Jenkinson, T. Cox, W. Greenhalf, C. Halloran, Joseph Tang, R. Sutton, J. Neoptolemos, Eithne Costello   +9 more
semanticscholar   +1 more source

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

New England Journal of Medicine, 2022
BACKGROUND KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.
J. Strickler, H. Satake, T. George, R. Yaeger, A. Hollebecque, I. Garrido-Laguna, M. Schuler, T. Burns, A. Coveler, G. Falchook, M. Vincent, Y. Sunakawa, L. Dahan, D. Bajor, S. Rha, C. Lemech, D. Juric, M. Rehn, G. Ngarmchamnanrith, Pegah Jafarinasabian, Q. Tran, D. Hong   +21 more
semanticscholar   +1 more source

Lifestyle Behaviors and Cardiotoxic Treatment Risks in Adult Childhood Cancer Survivors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Higher doses of anthracyclines and heart‐relevant radiotherapy increase cardiovascular disease (CVD) risk. This study assessed CVD and CVD risk factors among adult childhood cancer survivors (CCSs) across cardiotoxic treatment risk groups and examined associations between lifestyle behaviors and treatment risks.
Ruijie Li, Raquel Revuelta Iniesta, Alan R. Barker, Dimitris Vlachopoulos, Tomáš Sláma, Christina Schindera, Fabiën N. Belle   +6 more
wiley   +1 more source

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing

Cancer Medicine, 2022
Background The pre‐adjuvant chemotherapy (PAC) status of postoperative pancreatic ductal adenocarcinoma (PDAC) patients has not been studied and elaborated well previously.
Ningzhen Fu, Kai Qin, Jingfeng Li, Jiabin Jin, Yu Jiang, Xiaxing Deng, Baiyong Shen   +6 more
doaj   +1 more source

Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.

Journal of investigative surgery, 2022
Pancreatic cancer is one of the leading causes for cancer-related deaths in the United States. Majority of patients present with unresectable or metastatic disease.
H. Kolbeinsson, S. Chandana, G. Wright, M. Chung   +3 more
semanticscholar   +1 more source

Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Approximately 10% of patients with Ewing sarcoma (EwS) have pathogenic germline variants. Here, we report two cases: first, a novel germline pathogenic variant in partner and localizer of BRCA2 (PALB2) in a patient with a late EwS relapse. Its impact on homologous recombination is demonstrated, and breast cancer risk is discussed.
Molly Mack, A. Carolina Tufino, Mohd Azrin Jamalruddin, Sreya Dey, Yinghong Pan, Elina Mukherjee, Jessica D. Daley, Julia Meade, Mahmoud Aarabi, Lisa Maurer, James Cooper, Kara A. Bernstein, Kelly M. Bailey   +12 more
wiley   +1 more source